Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia

Department of Pathology, Stanford University, Stanford, CA; Department of Pathology, Weill Cornell Medical College, New York, NY; Department of Pathology, Massachusetts General Hospital, Boston, MA; Institute of Pathology, University of Cologne, Cologne, Germany; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD; Section of Hematology/Oncology, University of Chicago, Chicago, IL; Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH; Department of Molecular Medicine, University of Pavia, and Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and Department of Pathology, University of Chicago, Chicago, IL

[1]  T. Barbui,et al.  Myeloproliferative neoplasms: Morphology and clinical practice , 2016, American journal of hematology.

[2]  A. Tefferi,et al.  Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia , 2016, Blood Cancer Journal.

[3]  T. Walsh,et al.  Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemia , 2016, Cancer.

[4]  H. Gisslinger,et al.  Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria , 2015, Leukemia.

[5]  P. Valent.  Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. , 2015, Hematology. American Society of Hematology. Education Program.

[6]  S. Barrans,et al.  Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. , 2015, Blood.

[7]  J. Witte,et al.  MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. , 2015, Blood.

[8]  F. Fend,et al.  Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications , 2015, Modern Pathology.

[9]  G. Mufti,et al.  An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms , 2015, Haematologica.

[10]  W. Evans,et al.  BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures , 2015, Haematologica.

[11]  T. Barbui,et al.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis , 2015, Blood Cancer Journal.

[12]  M. Cazzola,et al.  Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene , 2015, Annals of Hematology.

[13]  P. Campbell,et al.  SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.

[14]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[15]  Sa A. Wang,et al.  Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing Entities. , 2015, American journal of clinical pathology.

[16]  J. Hernández-Rivas,et al.  Deregulation of Genes Related to Iron and Mitochondrial Metabolism in Refractory Anemia with Ring Sideroblasts , 2015, PloS one.

[17]  R. Hehlmann.  CML—where do we stand in 2015? , 2015, Annals of Hematology.

[18]  Franco Locatelli,et al.  How I treat juvenile myelomonocytic leukemia. , 2015, Blood.

[19]  P. Campbell,et al.  Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. , 2015, Blood.

[20]  P. Campbell,et al.  Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes , 2015, Nature Communications.

[21]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[22]  M. Loh,et al.  T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434 , 2014 .

[23]  U. Germing,et al.  Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. , 2014, Leukemia research.

[24]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[25]  J. Radich,et al.  Chronic myelogenous leukemia, version 1.2015. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[26]  T. Barbui,et al.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. , 2014, Blood.

[27]  Y. Nojima,et al.  Philadelphia chromosome‐positive mixed phenotype acute leukemia in the imatinib era , 2014, European journal of haematology.

[28]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[29]  B. Bain,et al.  Should myeloid and lymphoid neoplasms with PCM1‐JAK2 and other rearrangements of JAK2 be recognized as specific entities? , 2014, British journal of haematology.

[30]  D. Neuberg,et al.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Wade,et al.  Outcome for children and young people with Early T‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003 , 2014, British journal of haematology.

[32]  R. Bejar.  Clinical and genetic predictors of prognosis in myelodysplastic syndromes , 2014, Haematologica.

[33]  G. Mufti,et al.  p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) , 2014, Haematologica.

[34]  D. Birnbaum,et al.  Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia , 2014, American journal of hematology.

[35]  S. Ascani,et al.  Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms , 2014, Modern Pathology.

[36]  A. Kohlmann,et al.  Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93% , 2014, Genes, chromosomes & cancer.

[37]  P. Campbell,et al.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes , 2014, Leukemia.

[38]  J. Esteve,et al.  Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1 , 2014, Annals of Hematology.

[39]  J. Tchinda,et al.  An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome , 2014, Leukemia.

[40]  F. Stingo,et al.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. , 2014, Blood.

[41]  J. D. Engel,et al.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. , 2014, Cancer cell.

[42]  Britta A. M. Bouwman,et al.  A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia , 2014, Cell.

[43]  L. Godley,et al.  Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations , 2014, Annals of the New York Academy of Sciences.

[44]  C. Nakaseko,et al.  Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status , 2014, International Journal of Hematology.

[45]  T. Barbui,et al.  An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms , 2014, Leukemia.

[46]  F. Şahin,et al.  Granulocytic sarcoma: a systematic review. , 2013, American journal of blood research.

[47]  M. Ehinger,et al.  World Health Organization‐defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations—The Danish experience , 2013, American journal of hematology.

[48]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[49]  T. Barbui,et al.  Masked polycythemia Vera (mPV): Results of an international study , 2018, American journal of hematology.

[50]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[51]  S. Miyano,et al.  The landscape of somatic mutations in Down syndrome–related myeloid disorders , 2013, Nature Genetics.

[52]  M. Loh,et al.  Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Mullighan,et al.  Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  L. Bullinger,et al.  The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. , 2013, Blood.

[55]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[56]  D. Birnbaum,et al.  Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  L. Arenillas,et al.  Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations , 2013, British journal of haematology.

[58]  S. Bohlander,et al.  Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. , 2013, Blood.

[59]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[60]  Angela G. Fleischman,et al.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. , 2013, The New England journal of medicine.

[61]  R. Hills,et al.  Does BCR/ABL1 positive Acute Myeloid Leukaemia Exist? , 2013, British journal of haematology.

[62]  R. Warnke,et al.  Indolent T-Lymphoblastic Proliferation (iT-LBP): A Review of Clinical and Pathologic Features and Distinction from Malignant T-Lymphoblastic Lymphoma , 2013, Advances in anatomic pathology.

[63]  C Haferlach,et al.  SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations , 2013, Leukemia.

[64]  L. Arenillas,et al.  Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes , 2013, Haematologica.

[65]  E. Estey,et al.  Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. , 2013, Blood.

[66]  R. Kralovics,et al.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. , 2013, Blood.

[67]  T. Haferlach,et al.  Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 , 2013, Annals of Hematology.

[68]  F. Fend,et al.  Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease , 2013, Modern Pathology.

[69]  E. Thiel,et al.  FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors , 2013, PloS one.

[70]  Robert Huether,et al.  The genomic landscape of hypodiploid acute lymphoblastic leukemia , 2013, Nature Genetics.

[71]  M. Cazzola,et al.  Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. , 2013, Blood.

[72]  Roberta Spinelli,et al.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia , 2012, Nature Genetics.

[73]  A. Kohlmann,et al.  Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics , 2013, Leukemia.

[74]  D. Neuberg,et al.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[76]  Guido Marcucci,et al.  RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Ryan D. Morin,et al.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.

[78]  P. Vyas,et al.  Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. , 2012, Seminars in fetal & neonatal medicine.

[79]  L. Medeiros,et al.  Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML , 2012, PloS one.

[80]  M. Konopleva,et al.  Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia , 2012, Leukemia & lymphoma.

[81]  U. Germing,et al.  Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. , 2012, Leukemia research.

[82]  A. Kohlmann,et al.  Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. , 2012, Blood.

[83]  Gerhard Ehninger,et al.  Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors , 2012, Haematologica.

[84]  G. Barosi,et al.  Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis , 2012, PloS one.

[85]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[86]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  D. Campana,et al.  Clinical significance of early T‐cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children’s Cancer Study Group Study L99‐15 , 2012, British journal of haematology.

[88]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[89]  A. Tefferi,et al.  Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. , 2011, Blood.

[90]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[91]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[92]  A. Porwit,et al.  Acute myeloid leukemia with expanded erythropoiesis , 2011, Haematologica.

[93]  T. Barbui,et al.  Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[95]  H. Gisslinger,et al.  Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. , 2011, Blood.

[96]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Verena I Gaidzik,et al.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  T. Haferlach,et al.  RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. , 2011, Blood.

[99]  J. Esteve,et al.  The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. , 2010, Blood.

[100]  J. Meijerink.  Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. , 2010, Best practice & research. Clinical haematology.

[101]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[102]  R. Hills,et al.  Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  G. Ossenkoppele,et al.  Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification , 2010, Leukemia.

[104]  Paola Fazi,et al.  Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). , 2010, Blood.

[105]  S. Corti,et al.  RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant , 2010, Clinical Cancer Research.

[106]  H. Kantarjian,et al.  Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. , 2010, Blood.

[107]  Chieh-Yu Liu,et al.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.

[108]  A. Kohlmann,et al.  AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. , 2009, Blood.

[109]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[110]  H. Tien,et al.  Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’ , 2009, British Journal of Cancer.

[111]  Bas J. Wouters,et al.  Brief Report Results and Discussion , 2022 .

[112]  T. Pabst,et al.  Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis , 2009, British Journal of Cancer.

[113]  Cheng Cheng,et al.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.

[114]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[115]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[116]  J. Merker,et al.  Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. , 2008, Blood.

[117]  U. Germing,et al.  The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features , 2008, Leukemia.

[118]  A. Hagemeijer,et al.  A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification , 2007, Leukemia.

[119]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[120]  J. Buckley,et al.  Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. , 1998, Blood.

[121]  J. Harbott,et al.  Chronic myelomonocytic leukemia in childhood. A retrospective analysis of 110 cases. , 1997 .

[122]  C. Stiller,et al.  Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. , 1995, Blood.

[123]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.

[124]  P. Sharma,et al.  Inherited Mutations in Cancer Susceptibility Genes Are Common Among Survivors of Breast Cancer Who Develop Therapy-Related Leukemia , 2016 .

[125]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[126]  W. Evans,et al.  BCR-ABL 1-like cases in pediatric acute lymphoblastic leukemia : a comparison between DCOG / Erasmus MC and COG / St , 2015 .

[127]  M. Deininger.  Diagnosing and managing advanced chronic myeloid leukemia. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[128]  E. Jabbour,et al.  CME Information: Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management , 2014 .

[129]  U. Germing,et al.  Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. , 2013, Leukemia research.

[130]  P. Font,et al.  Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification , 2012, Annals of Hematology.

[131]  R. Schlenk,et al.  Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.

[132]  R. Pieters,et al.  University of Groningen Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia Hollink, , 2011 .

[133]  A. Órfão,et al.  Mixed phenotype acute leukemia (MPAL): clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification Authors: , 2011 .

[134]  C. Steidl,et al.  Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q , 2011, Leukemia.

[135]  R. Arceci.  Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia , 2010 .